Menstrual migraine: A review of prophylactic therapies

被引:27
作者
Martin V.T. [1 ]
机构
[1] University of Cincinnati, Div. of General Internal Medicine, Cincinnati, OH 45267-0535
关键词
Migraine; Sumatriptan; Naproxen Sodium; Migraine Headache; Migraine With Aura;
D O I
10.1007/s11916-004-0057-1
中图分类号
学科分类号
摘要
Menstrual migraine is commonly encountered in women who are experiencing attacks of migraine without aura. It remains controversial whether attacks of menstrually associated migraine are more severe and have a longer duration than non-menstrually associated attacks. The pathogenesis of menstrual migraine is not understood completely, but it may be related to estrogen withdrawal or prostaglandin release. Preventative therapies may be considered in those who have failed abortive medications or have attacks lasting longer than 2 days. They can be administered short-term during the perimenstrual time period or continuously throughout the menstrual cycle. Short-term prophylactics should be tried first because menstrual migraines generally last for 1 to 4 days only. Continuous prophylactics may be considered in those with attacks refractory to short-term therapies. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:229 / 237
页数:8
相关论文
共 70 条
[41]  
Sances G., Martignoni E., Fioroni L., Et al., Naproxen sodium in menstrual migraine prophylaxis: A double-blind, placebo-controlled study, Headache, 30, pp. 705-709, (1990)
[42]  
Szekely B., Merryman S., Croft H., Et al., Prophylactic effects of naproxen sodium on perimenstrual headache: A double-blind, placebo-controlled study, Cephalalgia, 9, SUPPL. 10, pp. 452-453, (1989)
[43]  
Gallagher R.M., Menstrual migraine and intermittent ergonovine therapy, Headache, 29, pp. 366-367, (1989)
[44]  
D'Alessandro R., Gamberini G., Lozito A., Et al., Menstrual migraine: Intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine, Cephalalgia, 3, SUPPL. 1, pp. 156-158, (1983)
[45]  
de Lignieres B., Vincens M., Mauvais-Jarvis P., Et al., Prevention of menstrual migraine by percutaneous oestradiol, Br. Med. J., 293, (1986)
[46]  
Dennerstein L., Morse C., Burrows G., Et al., Menstrual migraine: A double-blind trial of percutaneous estradiol, Gynecol. Endocrinol., 2, pp. 113-120, (1988)
[47]  
MacGregor A., Frith A., Ellis J., Et al., Estrogen "withdrawal:" a trigger for migraine? A double-blind, placebo-controlled study of estrogen supplements in the late luteal phase in women with migraine, Cephalalgia, 23, (2003)
[48]  
Pfaffenrath V., Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine, Cephalalgia, 13, SUPPL. 13, (1993)
[49]  
Smits M.G., van der Meer Y.G., Pfeil J.P., Et al., Perimenstrual migraine: Effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test, Headache, 34, pp. 103-106, (1994)
[50]  
Pradalier A., Vincent D., Beaulieu P., Et al., Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine, New Advances in Headache Research, pp. 129-132, (1994)